Pliant TherapeuticsPLRX +0.88%31 EV-to-FCF is 0.74 as of Jun. 27, 2026. GuruFocus rates PLRX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 333 Biotechnology companies, Pliant Therapeutics ranks better than 81.08% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pliant Therapeutics's Enterprise Value is $-73.07 Mil.
Pliant Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-98.81 Mil. Therefore, Pliant Therapeutics's EV-to-FCF for today is 0.74.
The historical rank and industry rank for Pliant Therapeutics's EV-to-FCF or its related term are showing as below:
PLRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -148.77 Med: -3.14 Max: 59.03
Current: 0.74
During the past 8 years, the highest EV-to-FCF of Pliant Therapeutics was 59.03. The lowest was -148.77. And the median was -3.14.
PLRX's EV-to-FCF is ranked better than 81.08% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs PLRX: 0.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pliant Therapeutics's PE Ratio (TTM) for today is calculated as:
Pliant Therapeutics's share price for today is $1.115.
Pliant Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pliant Therapeutics EV-to-FCF Related Terms
Pliant Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pliant Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pliant Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pliant Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pliant Therapeutics's EV-to-FCF falls into.
Pliant Therapeutics's current Enterprise Value is $-73.07 Mil.
Pliant Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pliant Therapeutics (PLRX) has a EV-to-FCF of 0.74 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pliant Therapeutics and its competitors. According to the industry distribution chart, Pliant Therapeutics ranks #63 out of 333 companies in the Biotechnology industry, placing it in the top 18.9%.
Is Pliant Therapeutics' EV-to-FCF too high?
Pliant Therapeutics' current EV-to-FCF is 0.74. The Biotechnology industry median EV-to-FCF is 14.65. Pliant Therapeutics' value of 0.74 is 94.9% below this industry median. Based on the distribution chart, Pliant Therapeutics ranks #63 out of 333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pliant Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pliant Therapeutics' EV-to-FCF compare to RLYB and LIXT?
According to the Biotechnology industry distribution chart, Pliant Therapeutics ranks #63 out of 333 companies for EV-to-FCF. This places Pliant Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.65. Pliant Therapeutics' value of 0.74 is 94.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pliant Therapeutics's current EV-to-FCF of 0.74 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pliant Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pliant Therapeutics's current EV-to-FCF is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pliant Therapeutics stock overvalued right now?
Pliant Therapeutics (PLRX) has a current EV-to-FCF of 0.74. The current EV-to-FCF is 0.74 and 94.9% below the Biotechnology industry median of 14.65. Pliant Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pliant Therapeutics (PLRX), the current EV-to-FCF is 0.74 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
31GF Score
Get the complete analysis for PLRX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLRX has been successfully added to your 
